National Bank of Canada’s AstraZeneca AZN Stock Holding History

National Bank of Canada’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.9M	Sell	447,620 -1,689,891	-79%	-$318M	0.06%	238
2026 Q1	$418M	Buy	2,137,511 +1,019,479	+91%	+$197M	0.37%	51
2025 Q4	$206M	Buy	1,118,032 +558,436	+100%	+$97.9M	0.19%	99
2025 Q3	$85.9M	Buy	559,596 +429,131	+329%	+$64.9M	0.09%	197
2025 Q2	$18.3M	Buy	130,465 +64,147	+97%	+$8.99M	0.02%	581
2025 Q1	$9.74M	Sell	66,318 -22,589	-25%	-$3.27M	0.01%	723
2024 Q4	$11.7M	Buy	88,907 +9,742	+12%	+$1.36M	0.01%	720
2024 Q3	$12.3M	Buy	79,165 +27,737	+54%	+$4.48M	0.01%	617
2024 Q2	$8.01M	Sell	51,428 -53,756	-51%	-$8.09M	0.01%	620
2024 Q1	$16.2M	Sell	105,184 -150,914	-59%	-$20M	0.02%	475
2023 Q4	$35M	Sell	256,098 -145,207	-36%	-$18.9M	0.06%	294
2023 Q3	$53.4M	Sell	401,305 -5,178	-1%	-$707K	0.08%	217
2023 Q2	$53.4M	Buy	406,483 +38,832	+11%	+$5.71M	0.1%	173
2023 Q1	$51.2M	Buy	367,651 +258,226	+236%	+$34.7M	0.13%	140
2022 Q4	$14.8M	Buy	109,425 +994	+0.9%	+$125K	0.04%	330
2022 Q3	$11.8M	Sell	108,431 -2,953	-3%	-$375K	0.06%	329
2022 Q2	$14.7M	Sell	111,384 -160	-0.1%	-$21K	0.07%	310
2022 Q1	$15.2M	Sell	111,544 -54,910	-33%	-$6.58M	0.04%	359
2021 Q4	$19.4M	Buy	+166,454	New	+$19.6M	0.07%	238

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

National Bank of Canada's AZN Position: Q2 2026 in Review

National Bank of Canada reduced its AstraZeneca (AZN) stake by 79% in Q2 2026, selling an estimated $318M and leaving 447,620 shares worth $85.9M. The position accounts for 0.06% of the portfolio, ranked #238.

National Bank of Canada first reported a position in AZN in Q4 2021 and has held it in 19 quarters since. The position peaked at $418M in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

National Bank of Canada held 447,620 shares of AstraZeneca worth $85.9M as of Q2 2026.
National Bank of Canada sold 1,689,891 AstraZeneca shares in Q2 2026, an estimated $318M.
AstraZeneca made up 0.06% of National Bank of Canada's portfolio in Q2 2026, its #238 holding.
National Bank of Canada first reported a position in AstraZeneca in Q4 2021 and has held it in 19 quarters since.
National Bank of Canada's AstraZeneca position peaked at $418M in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.